Proteinuria Clinical Trials

14 recruiting

Proteinuria Trials at a Glance

15 actively recruiting trials for proteinuria are listed on ClinicalTrialsFinder across 6 cities in 35 countries. The largest study group is Phase 2 with 4 trials, with the heaviest enrollment activity in Seattle, Adana, and Aguascalientes. Lead sponsors running proteinuria studies include Bayer, Christoph Aufricht, and AstraZeneca.

Browse proteinuria trials by phase

Treatments under study

About Proteinuria Clinical Trials

Looking for clinical trials for Proteinuria? There are currently 14 studies actively recruiting participants. Clinical trials offer access to new treatments before they are widely available, and every approved therapy in use today was first tested through a clinical trial.

Below you can browse trials, sign up for alerts when new Proteinuria trials open, and view eligibility criteria for each study. Each listing includes the study phase, locations, and enrollment details.

Frequently Asked Questions

Common questions about Proteinuria clinical trials

A clinical trial is a carefully designed research study that tests new medical treatments, drugs, devices, or approaches in human volunteers. Every approved medication and treatment available today was proven safe and effective through clinical trials.

All clinical trials are reviewed and approved by Institutional Review Boards (IRBs) — independent committees that evaluate patient safety. Trials follow strict protocols, and your health is monitored closely throughout. You can withdraw at any time.

Not necessarily. Many trials compare the new treatment against the current standard of care, meaning all participants receive active treatment. When placebos are used, they are typically combined with standard treatment, not given alone. The trial description will always specify the design.

Under the Affordable Care Act, most private insurers are required to cover routine patient care costs during a clinical trial. The sponsor typically covers the investigational treatment itself. Medicare also covers routine costs for qualifying trials.

Yes. Participation is completely voluntary. You can withdraw at any time, for any reason, without it affecting your access to standard medical care.

Each trial has specific eligibility criteria — including age, diagnosis, disease stage, prior treatments, and general health. Browse the trials listed above and check their eligibility sections. You can also contact the trial site directly to discuss your situation.

Showing 115 of 15 trials

Recruiting
Not Applicable

A Smart Phone Application to Improve Adoption of the 2024 Kidney Disease Improving Global Outcomes (KDIGO) Chronic Kidney Disease (CKD) Guidelines

Chronic Kidney DiseaseProteinuriaBlood Pressure Control+2 more
St. James's Hospital, Ireland80 enrolled2 locationsNCT07561957
Recruiting
Phase 2

Rituximab Plus Cyclosporine in Idiopathic Membranous Nephropathy

Autoimmune DiseaseProteinuriaGlomerular Disease+2 more
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)30 enrolled2 locationsNCT00977977
Recruiting
Phase 3

A Study to Learn More About How Well the Study Treatment Finerenone Works, How Safe it is, How it Moves Into, Through, and Out of the Body, and the Effects it Has on the Body When Taken With an ACE Inhibitor or Angiotensin Receptor Blocker in Children With Chronic Kidney Disease and Proteinuria

Chronic Kidney DiseaseProteinuria
Bayer219 enrolled164 locationsNCT05196035
Recruiting
Phase 2

A Study to Investigate the Effects of Zibotentan/Dapagliflozin Combination Compared to Dapagliflozin Alone in Adult Participants With Chronic Kidney Disease and High Proteinuria

Chronic Kidney Disease With High Proteinuria
AstraZeneca224 enrolled15 locationsNCT06942910
Recruiting
Phase 3

A Study to Learn More About How Safe the Study Treatment Finerenone is in Long-term Use When Taken With an ACE Inhibitor or Angiotensin Receptor Blocker Over 18 Months of Use in Children and Young Adults From 1 to 18 Years of Age With Chronic Kidney Disease and Proteinuria

Chronic Kidney DiseaseProteinuriaChildren
Bayer100 enrolled178 locationsNCT05457283
Recruiting
Phase 2

A Study of the Safety, Tolerability, Pharmacokinetics and Efficacy of Treatment With AP1189 in Patients With iMN and Severe Proteinuria

Nephrotic Syndrome Due to Idiopathic Membranous NephropathySevere Proteinuria Due to Idiopathic Membranous Nephropathy
SynAct Pharma Aps23 enrolled1 locationNCT04456816
Recruiting
Phase 4

Sparsentan in Posttransplant Immunoglobulin A Nephropathy or Focal Segmental Glomerulosclerosis

Kidney TransplantFocal Segmental GlomerulosclerosisProteinuria+1 more
Travere Therapeutics, Inc.20 enrolled9 locationsNCT07219121
Recruiting

Pediatric Hypertension and the Renin-Angiotensin SystEm (PHRASE)

Autonomic DysfunctionHypertensionBlood Pressure Disorders+15 more
Wake Forest University Health Sciences125 enrolled1 locationNCT04752293
Recruiting

Proteinuria in Pre and Post Transplant

Proteinuria
University of Miami100 enrolled1 locationNCT01094327
Recruiting
Phase 4

Nefecon and Ambrisentan in IgA Nephropathy

Chronic Kidney DiseaseIgA NephropathyProteinuria
The First Hospital of Jilin University129 enrolled1 locationNCT07030894
Recruiting

PEPPI Study: Identification of Women at Risk for Placental Dysfunction

Cardiovascular DiseasesPolycystic Ovary SyndromePre-Eclampsia+4 more
Oulu University Hospital3,000 enrolled1 locationNCT06115122
Recruiting
Phase 2

Beneficial Effect of Amiloride on Progression of Chronic Kidney Disease

Chronic Kidney Disease(CKD)Proteinuria
Odense University Hospital40 enrolled1 locationNCT06923709
Recruiting
Not Applicable

Effects of Exogenous Ketosis on Proteinuria and Renal Function

KetosisProteinuriaRenal Insufficiency, Chronic+1 more
Gødstrup Hospital43 enrolled1 locationNCT06867471
Recruiting

Improving Renal Complications in Adolescents With Type 2 Diabetes Through REsearch Cohort Study (National iCARE Study)

StressType 2 DiabetesProteinuria+1 more
University of Manitoba500 enrolled1 locationNCT02818192
Recruiting

ARREST-NEPHROSIS - Austrian Resistant Nephrotic Syndrome Treatment Response Registry and Biobank

Focal Segmental GlomerulosclerosisProteinuriaNephrotic Syndrome+1 more
Christoph Aufricht100 enrolled1 locationNCT06162546